

*Contains Nonbinding Recommendations*

*Draft – Not for Implementation*

# Dental Curing Lights - Premarket Notification (510(k)) Submissions

---

## Draft Guidance for Industry and Food and Drug Administration Staff

***DRAFT GUIDANCE***

**This draft guidance document is being distributed for comment purposes only.**

**Document issued on July 12, 2024.**

You should submit comments and suggestions regarding this draft document within 60 days of publication in the *Federal Register* of the notice announcing the availability of the draft guidance. Submit electronic comments to <https://www.regulations.gov>. Submit written comments to the Dockets Management Staff, Food and Drug Administration, 5630 Fishers Lane, Room 1061, (HFA-305), Rockville, MD 20852. Identify all comments with the docket number listed in the notice of availability that publishes in the *Federal Register*.

For questions about this document, contact OHT1: Office of Ophthalmic, Anesthesia, Respiratory, ENT and Dental Devices/DHT1B: Division of Dental and ENT Devices at 301-796-5620.

**When final, this guidance will supersede “Dental Curing Lights – Premarket Notification [510(k)] Submissions” issued March 27, 2006.**



U.S. Department of Health and Human Services  
Food and Drug Administration  
Center for Devices and Radiological Health

*Contains Nonbinding Recommendations*

*Draft – Not for Implementation*

# **Preface**

## **Additional Copies**

Additional copies are available from the Internet. You may also send an email request to [CDRH-Guidance@fda.hhs.gov](mailto:CDRH-Guidance@fda.hhs.gov) to receive a copy of the guidance. Please include the document number GUI00016017 and complete title of the guidance in the request.

DRAFT

*Contains Nonbinding Recommendations*

*Draft – Not for Implementation*

**Table of Contents**

I.	Introduction .....	1
II.	Scope .....	2
III.	Premarket Submission Recommendations .....	2
A.	Device Description.....	2
B.	Predicate Comparison .....	3
C.	Labeling .....	3
D.	Reprocessing.....	4
E.	Biocompatibility .....	5
F.	Software .....	6
G.	Cybersecurity .....	7
H.	Electrical Safety and Electromagnetic Compatibility (EMC) .....	7
I.	Wireless Technology .....	8
J.	Non-Clinical Performance Testing .....	8
(1)	Radiant power output.....	8
(2)	Heat generation.....	9
(3)	Depth of cure .....	9
IV.	Modifications.....	10

# Dental Curing Lights - Premarket Notification (510(k)) Submissions

## Draft Guidance for Industry and Food and Drug Administration Staff

*This draft guidance, when finalized, will represent the current thinking of the Food and Drug Administration (FDA or Agency) on this topic. It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. To discuss an alternative approach, contact the FDA staff or Office responsible for this guidance as listed on the title page.*

### I. Introduction

This draft guidance document provides recommendations for 510(k) submissions for dental curing lights. The devices in the scope of this guidance emit non-ionizing optical radiation intended to photopolymerize dental restorative resins. FDA is issuing this draft guidance to clarify and provide recommendations for premarket submissions for dental curing lights, as well as reference relevant consensus standards. The recommendations are intended to promote consistency and facilitate efficient review of these submissions.

This guidance, when final, will supersede the guidance “[Dental Curing Lights – Premarket Notification \[510\(k\)\] Submissions](#)” issued March 27, 2006. This document supplements other FDA documents regarding the specific content requirements of a premarket notification (510(k)) submission. You should also refer to 21 CFR 807.87 and FDA’s guidance, “[Electronic Submission Template for Medical Device 510\(k\) Submissions](#).”

For the current edition of the FDA-recognized consensus standard(s) referenced in this document, see the [FDA Recognized Consensus Standards Database](#). If submitting a Declaration of Conformity to a recognized standard, we recommend you include the appropriate supporting documentation. For more information regarding use of consensus standards in regulatory submissions, please refer to the FDA guidance titled “[Appropriate Use of Voluntary Consensus Standards in Premarket Submissions for Medical Devices](#).”

In general, FDA’s guidance documents do not establish legally enforceable responsibilities. Instead, guidances describe the Agency’s current thinking on a topic and should be viewed only as recommendations, unless specific regulatory or statutory requirements are cited. The use of

*Contains Nonbinding Recommendations*

*Draft – Not for Implementation*

38 the word *should* in Agency guidances means that something is suggested or recommended, but  
39 not required.

40

41 **II. Scope**

42 The scope of this document is limited to dental curing lights regulated under 21 CFR 872.6070  
43 and with the product code listed in the table below:

44

45

**Table 1: Applicable Product Code**

<b>Product Code</b>	<b>Product Code Name</b>	<b>Regulation Number</b>
EBZ	Activator, Ultraviolet, for Polymerization	21 CFR 872.6070

46

47 The scope of this document does not include laser devices for polymerization such as those  
48 regulated under 21 CFR 878.4810 or under 21 CFR 872.6070 with the product code QNF and  
49 devices that use heat, light, or other energy sources exclusively for tooth whitening (bleaching)  
50 procedures. Devices intended exclusively for tooth bleaching are class I exempt regulated under  
51 21 CFR 872.6475, with product code EEG.

52

53 **III. Premarket Submission Recommendations**

54 **A. Device Description**

55 We recommend that you identify your device by the applicable regulation number and product  
56 code indicated in Section II above and include the information described below.

57

58 As part of the device description, we recommend that you provide a complete description of all  
59 components, patient contacting materials, and features of the dental curing light devices,  
60 including the following information:

- 61 • Labeled images and/or illustrations of all components that comprise the device;
- 62 • Descriptions of any accessories and/or protective equipment that are packaged with the  
63 device, e.g., radiometer, filters, shields, light guides, protective filter glasses;
- 64 • Engineering drawings and/or schematics of the interior of the device, particularly the  
65 light assembly;
- 66 • Descriptions of the power source, battery type, capacity, and electrical characteristics  
67 (e.g., frequency, voltage);
- 68 • Descriptions of the light source, number and placement of light sources (particularly for  
69 LEDs), and wattage; and
- 70 • Descriptions of all operational modes and any controls, sensors, or alarms.

*Contains Nonbinding Recommendations*

*Draft – Not for Implementation*

71 **B. Predicate Comparison**

72 For devices reviewed under the 510(k) process, manufacturers must compare their new device to  
73 a similar legally marketed predicate device to support its substantial equivalence (section 513(i)  
74 of the Federal Food, Drug and Cosmetic Act (FD&C Act); 21 CFR 807.87(f)). This comparison  
75 should provide information to show how your device is similar to and different from the  
76 predicate. Side by side comparisons, whenever possible, are desirable. See below for an example  
77 of how this information may be organized. This table is not intended to represent an exhaustive  
78 list of comparative parameters; ensure you provide all relevant device descriptive and  
79 performance characteristics.  
80

81 **Table 2: Sample predicate comparison table to outline differences and similarities between**  
82 **the subject and predicate devices.**

Description	Subject Device	Predicate Device (Kxxxxxx)
Indications for use		
Operational modes		
Light source		
Power source		
Accessories		
Maximum light intensity (or irradiance) (mW/cm <sup>2</sup> )		
Radiant power output (or radiant flux) (mW)		
Peak wavelength (nm)		
Radiant exposure output range (J/cm <sup>2</sup> )		
Composition of patient-contacting portions of device		
Other relevant characteristics...		

83

84 **C. Labeling**

85 The premarket notification must include proposed labeling in sufficient detail to satisfy the  
86 requirements of 21 CFR 807.87(e). Proposed labels and labeling, sufficient to describe the dental  
87 curing light, its intended use, and the directions for use must be provided.  
88

89 As prescription devices, dental curing lights are exempt from the requirement to have adequate  
90 directions for lay use required under section 502(f)(1) of the FD&C Act as long as the conditions  
91 in 21 CFR 801.109 are met. For instance, to be so exempt, labeling that furnishes information  
92 for use of the prescription device must, among other things, contain adequate information for  
93 such use, including indications, effects, routes, methods, and frequency, and duration of  
94 administration and any relevant hazards, contraindications, side effects and precautions, under  
95 which practitioners licensed by law to employ the device can use the device safely and for the  
96 purposes for which it is intended (21 CFR 801.109(d)).  
97

98 We recommend that the instructions for use include the following information:

## *Contains Nonbinding Recommendations*

### *Draft – Not for Implementation*

- 99 • Total radiant power output (or radiant flux) (mW) throughout the exposure cycle;
- 100 • Maximum light intensity (or irradiance) (mW/cm<sup>2</sup>);
- 101 • Peak wavelength (nm);
- 102 • Radiant exposure (or optical radiation dose) output range (J/cm<sup>2</sup>);
- 103 • Recommended distance (mm) and angle (degrees) of use from the tooth surface;
- 104 • Recommended curing time(s);
- 105 • Instructions for the use of disposable sleeves for non-patient contacting portions of the  
106 device, as applicable;
- 107 • Instructions for the use of protective equipment such as shields, filter glasses, etc., as  
108 applicable, in accordance with the currently FDA-recognized versions of ISO 12609-1  
109 *Eyewear for protection against intense light sources used on humans and animals for*  
110 *cosmetic and medical applications -- Part 1: Specification for products* and ISO 12609-2  
111 *Eyewear for protection against intense light sources used on humans and animals for*  
112 *cosmetic and medical applications -- Part 2: Guidance for use;*
- 113 • Instructions on how to periodically check the irradiance output;
- 114 • Warnings about thermal hazards; and
- 115 • Reuse information as described in FDA guidance “[Reprocessing Medical Devices in](#)  
116 [Health Care Settings: Validation Methods and Labeling.](#)” Specifically, we recommend  
117 that your instructions for reprocessing address disassembly, cleaning,  
118 disinfection/sterilization, and reassembly of the device.

#### 119 **D. Reprocessing**

120 Significance: Many of the patient contacting components of dental curing lights are reused, and  
121 should be adequately cleaned, disinfected and sterilized between uses to minimize infections  
122 while preventing device degradation.

123  
124 Recommendation: Instructions on how to reprocess a reusable device are critical to ensure that a  
125 device is appropriately prepared for its initial and subsequent uses. For recommendations  
126 regarding the development and validation of reprocessing instructions in your proposed device  
127 labeling, refer to FDA’s guidance “[Reprocessing Medical Devices in Health Care Settings:](#)  
128 [Validation Methods and Labeling.](#)”

## *Contains Nonbinding Recommendations*

### *Draft – Not for Implementation*

#### 129 **E. Biocompatibility**

130 Significance: Dental curing lights contain patient-contacting materials, which, when used for  
131 their intended purpose, (i.e., contact type and duration), may induce a harmful biological  
132 response.

133  
134 Recommendation: You should determine the biocompatibility of all patient-contacting materials  
135 present in your device. If your device is identical in chemical composition, manufacturing and  
136 processing methods to dental curing lights with a history of safe use, you may reference previous  
137 testing experience or the literature, if appropriate. For some device materials, it may be  
138 appropriate to provide a reference to either a recognized consensus standard, or to a Letter of  
139 Authorization (LOA) for a device Master File (MAF). You should refer to the following FDA  
140 webpage for additional information on using device MAFs: [https://www.fda.gov/medical-](https://www.fda.gov/medical-devices/premarket-approval-pma/master-files)  
141 [devices/premarket-approval-pma/master-files](https://www.fda.gov/medical-devices/premarket-approval-pma/master-files).

142  
143 If you are unable to identify a legally marketed predicate device with the same nature of contact  
144 and contact duration that uses the same materials and manufacturing process as used in your  
145 device, we recommend you conduct and provide a biocompatibility evaluation as described in  
146 ISO 7405 *Dentistry - Evaluation of biocompatibility of medical devices used in dentistry* for the  
147 endpoints outlined below. Per FDA’s guidance “[Use of International Standard ISO 10993-1,](#)  
148 [‘Biological evaluation of medical devices - Part 1: Evaluation and testing within a risk](#)  
149 [management process’](#),” when FDA-recognized consensus standards exist for a particular device  
150 type, the biocompatibility recommendations in the device-specific consensus standard should be  
151 used instead of the recommendations outlined in ISO 10993-1. The biocompatibility evaluation  
152 should explain the relationship between the identified biocompatibility risks, the information  
153 available to mitigate the identified risks, and any knowledge gaps that remain. You should then  
154 identify any biocompatibility testing or other evaluations that were conducted to mitigate any  
155 remaining risks. We recommend that you consider the recommendations in the guidance or the  
156 standard, which identifies the types of biocompatibility assessments that should be considered  
157 and recommendations regarding how to conduct related tests.

158  
159 Per ISO 7405 *Dentistry - Evaluation of biocompatibility of medical devices used in dentistry* or  
160 ISO 10993-1 *Biological evaluation of medical devices – Part 1: Evaluation and testing within a*  
161 *risk management process* and Attachment A of FDA’s guidance on ISO-10993-1, dental curing  
162 lights are surface devices for a limited contact duration.

163  
164 The following endpoints should be addressed in your biocompatibility evaluation:

- 165 • cytotoxicity;
- 166 • sensitization; and
- 167 • irritation or intracutaneous reactivity.



## *Contains Nonbinding Recommendations*

### *Draft – Not for Implementation*

#### 168 **F. Software**

169 Significance: Device software function(s) in dental curing lights ensures control of the operation  
170 and output of the curing light. Adequate software testing provides assurance that the device  
171 functions as intended.

172  
173 Recommendation: Refer to the FDA premarket device software functions guidance “[Content of](#)  
174 [Premarket Submissions for Device Software Functions](#)” for a discussion of the software  
175 information that you should provide in your submission. The premarket software guidance  
176 outlines the recommended information to be provided in a premarket submission that includes a  
177 device software function based on the “Documentation Level” associated with the device. We  
178 generally consider the device software function(s) for dental curing lights to need a “Basic”  
179 Documentation Level. However, new or unusual indications, applications, or technological  
180 characteristics may result in an Enhanced Documentation Level.

181  
182 We recommend that you provide a full description of the device software function(s) supporting  
183 the operation of the subject device following this software guidance. This recommendation  
184 applies to original devices/systems as well as to any software changes made to already-marketed  
185 devices. Changes to software must be revalidated, reverified, and documented in accordance  
186 with Design Controls, 21 CFR 820.30(g)(i), and documented in the Design History File, 21 CFR  
187 820.30(j).<sup>1</sup> Some software changes may warrant the submission of a new 510(k). For further  
188 information on this topic, refer to “[Deciding When to Submit a 510\(k\) for a Software Change to](#)  
189 [an Existing Device.](#)”

190  
191 If the device includes off-the-shelf software, you should provide the additional information as  
192 recommended in the FDA guidances “[Off-the-Shelf Software Use in Medical Devices](#)” and  
193 “[Cybersecurity for Networked Medical Devices Containing Off-the-Shelf \(OTS\) Software.](#)”  
194 which provide additional information regarding medical devices utilizing off-the-shelf software.

195  
196 If the device is a multiple function device product and includes software function(s) that are  
197 considered “other functions,” as that term is used in the guidance “[Multiple Function Device](#)  
198 [Product: Policy and Considerations.](#)” the recommendations described in the aforementioned  
199 guidance should also be considered when preparing the software documentation for a premarket  
200 submission.

201

---

<sup>1</sup> On February 2, 2024, FDA issued a final rule amending the device quality system (QS) regulation, 21 CFR part 820, to align more closely with international consensus standards for devices. FDA also made conforming amendments to 21 CFR part 4 ([89 FR 7496](#)). This final rule will take effect on February 2, 2026. Once in effect, this rule will amend the majority of the current requirements in part 820 and incorporate by reference the 2016 edition of the International Organization for Standardization (ISO) 13485, Medical devices – Quality management systems – Requirements for regulatory purposes, in part 820. As stated in the final rule, the requirements in ISO 13485 are, when taken in totality, substantially similar to the requirements of the current part 820, providing a similar level of assurance in a firm’s quality management system and ability to consistently manufacture devices that are safe and effective and otherwise in compliance with the FD&C Act. When the final rule takes effect, FDA will also update the references to provisions in 21 CFR part 820 in this guidance to be consistent with that rule.

## *Contains Nonbinding Recommendations*

### *Draft – Not for Implementation*

202 Overall, documentation related to device software function(s) should provide sufficient evidence  
203 to describe the role of the software in the context of the device’s intended use and testing to  
204 demonstrate that the software functions as designed.

## 205 **G. Cybersecurity**

206 Significance: Dental curing lights contain software or firmware and have the ability to connect to  
207 the internet either directly or indirectly through the connectivity features present in the device  
208 design. Failure to maintain cybersecurity can result in risks such as compromised device  
209 functionality, loss of device availability, loss of data (medical or personal) availability or  
210 integrity, or exposure of other connected devices or networks to security threats. This in turn  
211 may have the potential to result in patient injury.

212  
213 Recommendation: If the device meets the definition of a cyber device under section 524B(c) of  
214 the FD&C Act, cybersecurity documentation under section 524B(b) of the FD&C Act is required  
215 as a part of the premarket submission. Refer to the FDA cybersecurity guidance “[Cybersecurity](#)  
216 [in Medical Devices: Quality System Considerations and Content of Premarket Submissions](#),” for  
217 a discussion of the cybersecurity documentation that you should provide in your submission.

## 218 **H. Electrical Safety and Electromagnetic Compatibility** 219 **(EMC)**

220 Significance: Dental curing lights are medical electrical equipment and therefore may expose  
221 the operator and patient to hazards associated with the use of electrical energy or may fail to  
222 operate properly in the presence of electromagnetic disturbance.

223 Recommendation: Dental curing lights should be tested to demonstrate that they perform as  
224 anticipated in their intended use environment. We recommend that this testing be performed as  
225 described in the currently FDA-recognized versions of the following standards for medical  
226 electrical equipment safety and electromagnetic compatibility:

- 227 • IEC 60601-1 *Medical electrical equipment – Part 1: General requirements for basic*  
228 *safety and essential performance (with relevant U.S. national differences applied)*
- 229 • IEC 80601-2-60 *Medical electrical equipment - Part 2-60: Particular requirements for*  
230 *the basic safety and essential performance of dental equipment*
- 231 • IEC 60601-1-2 *Medical electrical equipment – Part 1-2: General requirements for basic*  
232 *safety and essential performance – Collateral standard: Electromagnetic disturbances –*  
233 *Requirements and tests*

234 If submitting a Declaration of Conformity to the above standards, we recommend that  
235 appropriate supplemental documentation such as an assessment of the results and how  
236 conformity was determined. Information regarding test methods used should be provided  
237 because this series of standards includes general methods with multiple options and, in some  
238 cases, does not include specific acceptance criteria or address assessment of results. For

## *Contains Nonbinding Recommendations*

### *Draft – Not for Implementation*

239 additional information on providing electromagnetic compatibility information in a premarket  
240 submission, see FDA’s guidance, “[Electromagnetic Compatibility \(EMC\) of Medical Devices.](#)”

#### 241 **I. Wireless Technology**

242 Significance: In the design, testing, and use of wireless medical devices, the correct, timely, and  
243 secure transmission of medical data and information is essential for the safe and effective use of  
244 medical devices and systems.

245  
246 Recommendation: If your dental curing light incorporates radiofrequency wireless technology  
247 such as Bluetooth, IEEE 802.11 (Wi-Fi) or RFID (radio frequency identification) technology,  
248 testing beyond what is specified in the IEC 60601 standards is recommended to demonstrate that  
249 the wireless device functions will perform as intended in environments with other wireless  
250 products.

251  
252 We recommend that you consult FDA’s guidance “[Radio Frequency Wireless Technology in](#)  
253 [Medical Devices](#)” for additional recommendations on this topic.

#### 254 **J. Non-Clinical Performance Testing**

255 Non-clinical performance testing is recommended for dental curing lights to fully characterize  
256 the device. Descriptive characteristics alone are not sufficient to ensure that the devices can  
257 perform as intended for the end user. For information on the recommended content and format of  
258 test reports for the testing described in this section, refer to FDA’s guidance, “[Recommended](#)  
259 [Content and Format of Non-Clinical Bench Performance Testing Information in Premarket](#)  
260 [Submissions.](#)”

##### 261 **(1) Radiant power output**

262 Significance: Radiant power output (radiant flux) is a measure of the ability of dental curing  
263 lights to photopolymerize dental restorative resins. Inadequate radiant power output from dental  
264 curing lights can result in incomplete curing of dental restorative resins and lead to premature  
265 failure of the restorative material. Excessive radiant power output can result in a thermal hazard  
266 for both the patient and the provider. Testing on the type, amount, and uniformity of radiant  
267 power output provides assurance that the dental curing light will provide the appropriate amount  
268 of energy for its intended purpose.

269  
270 Recommendation: We recommend that you characterize the radiant power output delivered by  
271 the dental curing light source using test methods that conform to the following currently FDA-  
272 recognized consensus standard, ISO 10650 *Dentistry – Powered Polymerization Activators*.

273  
274 We recommend that you provide the results of testing that characterizes the radiant power output  
275 of your dental curing light. We recommend that you provide the following information:

- 276 • Total radiant power output (or radiant flux) (mW) throughout the total exposure cycle;

## *Contains Nonbinding Recommendations*

### *Draft – Not for Implementation*

- 277 • Maximum light intensity (or irradiance) ( $\text{mW}/\text{cm}^2$ ) measured at a distance of 2 mm from  
278 the distal end of the device light guide;
- 279 • Total spectral irradiance ( $\text{mW}/\text{cm}^2\text{-nm}$ ) plot at maximum irradiance output ( $\text{mW}/\text{cm}^2$ )  
280 versus wavelength (nm) at a distance of 2 mm from the distal end of the device light  
281 guide showing the peak wavelength (nm) and ultraviolet wavelengths (i.e.,  $< 385 \text{ nm}$ );
- 282 • Radiant exposure (or optical radiation dose) output range ( $\text{J}/\text{cm}^2$ ) calculated by  
283 multiplying irradiance ( $\text{mW}/\text{cm}^2$ ) outputs of the various curing modes by recommended  
284 curing times (s);
- 285 • Irradiance attenuation plot, which is the irradiance ( $\text{mW}/\text{cm}^2$ ) versus vertical distance  
286 (from 0 mm to 10 mm at 2 mm increments) from the device light guide tip; and
- 287 • Thermal image or beam profiler of cross section of light guide tip at maximum radiant  
288 exitance showing relative “hot” and “cold” spots across lateral surface of the device light  
289 guide tip.

### 290 **(2) Heat generation**

291 Significance: Heat generation is the ability of dental curing lights to accumulate heat during  
292 normal operation. Excessive heat generation by the dental curing light can present a thermal  
293 hazard to the patient and the practitioner. Testing on heat generated during normal operation  
294 helps ensure that the dental curing light will not present a thermal hazard when used for its  
295 intended purpose.

296  
297 Recommendation: We recommend that you provide data to demonstrate that during normal and  
298 single fault conditions, the temperature generated by the device remains safe for both the patient  
299 and the practitioner. This would include heat generated within the body of the device and at the  
300 distal tip. We recommend that you identify the maximum temperature ( $^{\circ}\text{C}$ ) of the body of the  
301 device and at 2 mm from the distal end of the device under normal and single fault conditions  
302 when operated under the worst-case scenario, i.e., for the highest radiant exposure ( $\text{J}/\text{cm}^2$ ).

### 303 **(3) Depth of cure**

304 Significance: Depth of cure is a measure of thickness of a dental restorative resin that can be  
305 cured by a dental curing light under typical operating conditions. Inadequate depth of cure can  
306 result in incomplete curing, structural deficiencies, and premature failure of the dental restorative  
307 resin device. Depth of cure testing provides assurance that the dental curing light will provide  
308 sufficient energy to harden the compatible resin within the recommended curing time.

309  
310 Recommendation: We recommend that you provide the depth of cure (mm) on a representative,  
311 legally marketed dental restorative resin sample after a clinically relevant curing time. FDA  
312 recommends 10s as a clinically relevant curing time. We also recommend that you identify the  
313 dental restorative resin that was tested in the submission.

314

315 **IV. Modifications**

316 21 CFR 807.81(a)(3) provides that a device change or modification “that could significantly  
317 affect the safety or effectiveness of the device” or represents a “major change or modification in  
318 the intended use of the device” requires a new 510(k).<sup>2</sup> For additional details, see FDA  
319 guidances “[Deciding When to Submit a 510\(k\) for a Change to an Existing Device](#)” and  
320 “[Deciding When to Submit a 510\(k\) for a Software Change to an Existing Device.](#)”  
321  
322

---

<sup>2</sup> Section 3308 of the Food and Drug Omnibus Reform Act of 2022 (FDORA), enacted as part of the Consolidated Appropriations Act, 2023, added section 515C “Predetermined Change Control Plans for Devices” to the FD&C Act (Pub. L. No. 117-328). Section 515C provides FDA with express authority to approve or clear PCCPs for devices requiring premarket approval or premarket notification. For example, section 515C provides that supplemental applications (section 515C(a)) and new premarket notifications (section 515C(b)) are not required for a change to a device that would otherwise require a premarket approval supplement or new premarket notification if the change is consistent with a PCCP approved or cleared by FDA. Section 515C also provides that FDA may require that a PCCP include labeling for safe and effective use of a device as such device changes pursuant to such plan, notification requirements if the device does not function as intended pursuant to such plan, and performance requirements for changes made under the plan. If you are interested in proposing a PCCP in your marketing submission, we encourage you to submit a Pre-Submission to engage in further discussion with CDRH. See FDA’s guidance “[Requests for Feedback and Meetings for Medical Device Submissions: The Q-Submission Program.](#)”